National Cancer Institute

What National Cancer Institute does

National Cancer Institute (NCI) Nagpur is a 470-bed quaternary care oncology centre (scalable to 700 beds) operating on a 25-acre campus with approximately 9.5 lakh sq.ft. of built-up area at Jamtha, Nagpur. It is registered as a charitable institution under the Bombay Public Trust Act, 1950 and Societies Registration Act, 1860, and is owned and operated by Dr Aabaji Thatte Sewa Aur Anusandhan Sanstha (DATSAAS). NCI provides comprehensive cancer care across Medical, Surgical, Radiation, Hemato, Pediatric, and Nuclear Medicine Oncology (including the recently launched Radiotheranostics facility), Bone Marrow Transplant, Robotic/Minvasive Surgery, and Pain & Palliative care, supported by advanced diagnostics (PET, MRI, CT, Gamma Camera), NABL-accredited labs (ISO 15189:2022 for Clinical Biochemistry and Hematology), and the full NABH-accredited clinical and support portfolio (first hospital in Central India to receive NABH Full Accreditation under the 6th Edition). Operational since 2012 and formally dedicated to the nation in 2023, it runs a city-centre surgical oncology facility in Dharampeth (since 2018), a 27-bed pediatric oncology ward with 3 PICUs, and cancer-screening/outreach programmes including the Ayushmati women's programme and a free HPV-testing cervical cancer screening initiative at NCI Jhajjar in partnership with AIIMS Delhi.

Commercially, NCI runs a hybrid sustainable-charity model: direct revenue from patient treatment fees (professional services covering diagnostics, chemotherapy, radiation therapy, surgery, and inpatient/outpatient services) and from academic programmes such as the Post Basic Diploma in Oncology Nursing (PBDON) and Post Graduate Diploma in Oncology Care (PGDOC), with a substantial free-care and subsidized-care channel funded by donations (e.g., Manav Seva Samiti ₹70 lakh donation, larger Tata Trusts support). Its go-to-market is largely sales-led via community outreach camps, screening drives, and awareness programs in underserved regions, complemented by an international patient services department that formalizes cross-border patient intake through government-to-government MoUs (Mauritius in August 2024, Guyana in 2025) and by an academic/clinical training pipeline through partnerships with Tata Trusts, IIT Bombay (CAR T-Cell), IIT Kharagpur/VECC/CNCI (nuclear medicine MSc), AIIMS Delhi, and MUHS Nashik.

Strategically, NCI is positioning itself as a regional reference centre for next-generation precision oncology in Central India, with in-development CAR T-Cell therapy and Particle Therapy, planned AI-driven cancer technologies via its academic affiliations, and a hub-and-spoke footprint anchored by the main Jamtha campus and a planned satellite diagnostics/daycare facility in an adjoining district under Tata Trusts support. The on-roll headcount of 501-1000 supports roughly 10,000 patients per year (~2,800 new registrations), which underpins both clinical scale and the registry-enabled research mission. There are no funding rounds, no public/parent investment, and no revenue disclosure; financial scale is best triangulated from capacity and pricing rather than filings.

Name

National Cancer Institute

Legal name

National Cancer Institute

Website

https://ncinagpur.in

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

501–1,000 employees

Short description

National Cancer Institute is a 470-bed quaternary care oncology centre in Nagpur, India (owned by the DATSAAS charitable trust) providing comprehensive cancer diagnostics, treatment, research, and outreach across all major oncology specialties, with subsidized charity care and government partnerships spanning Mauritius and Guyana.

Ownership category

akta.pro rank

Product category

Cancer Care Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Specialty (except Psychiatric and Substance Abuse) Hospitals (6223), Diagnostic Imaging Centers (621512)

SIC

Services-Hospitals (8060), Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro industry

PRIMARYHLAFAHAC

Oncology & Cancer Specialty Hospitals

Healthcare & Life Sciences/Healthcare Providers & Systems/Specialty Hospitals & Inpatient Specialty Care

SECONDARYHLAFABAI

Ambulatory Oncology Centers (Outpatient Chemo/Radiation)

Healthcare & Life Sciences/Healthcare Providers & Systems/Ambulatory & Outpatient Care Centers

SECONDARYHLAKAFAB

Medical Oncology

Healthcare & Life Sciences/Specialist Medical Practice/Hematology & Oncology

SECONDARYHLAKAFAC

Radiation Oncology

Healthcare & Life Sciences/Specialist Medical Practice/Hematology & Oncology

SECONDARYHLAIAGAI

Nuclear Medicine Clinical Services & Therapy Centers

Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

SECONDARYHLAFAJAK

Gynecologic Oncology & Women’s Cancer Centers

Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers

Keywords

• Cancer treatment services
• Oncology diagnostics
• Radiation therapy
• Pediatric oncology
• Cancer research programs

Headquarters

HQ city

Nagpur

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales, Others

Revenue model

1. Healthcare Service Fees: Direct patient care services including diagnostics, chemotherapy, radiation therapy, surgery, and inpatient/outpatient services. Revenue generated through treatment fees from patients.
2. Charitable Donations: Donations from philanthropists and organizations supporting cancer care. The institute operates on sustainable charity model with support from donors like Manav Seva Samiti (₹70 lakh donation).
3. Academic and Training Programs: Revenue from specialized oncology courses including Post Basic Diploma in Oncology Nursing (PBDON) and Post Graduate Diploma in Oncology Care (PGDOC), as well as training programs for medical professionals.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

National Cancer Institute (NCI) Nagpur is a 470-bed quaternary care comprehensive cancer centre that delivers end-to-end oncology services spanning Medical, Surgical and Radiation Oncology, Haemato-Oncology, Bone Marrow Transplant, Pediatric Oncology, Nuclear Medicine including Radiotheranostics, and supportive care. It also operates advanced diagnostic imaging (CT, MRI, PET, Mammography), laboratory medicine, cancer prevention and outreach programmes (including the Ayushmati women's screening initiative), academic courses such as PBDON, PGDOC and an MSc in Nuclear Medicine, and clinical research through domestic and international collaborations.

Product overview

National Cancer Institute (NCI) Nagpur is a 470-bed (scalable to 700 beds) quaternary care comprehensive cancer centre operated by Dr Aabaji Thatte Sewa Aur Anusandhan Sanstha. The institute offers an integrated portfolio of cancer care services organised across clinical specialties (Medical Oncology, Surgical Oncology, Radiation Oncology, Paediatric Oncology, Nuclear Medicine, Bone Marrow Transplant, Haemato-Oncology), diagnostic services (CT, MRI, PET-CT, Mammography, Radiology, Laboratory Medicine), and support services (Pharmacy, Physiotherapy, Dietetics, Psychology, Rehabilitation, Ambulance). The core clinical platform is supplemented by Cancer Research, the Division of Cancer Statistics and Informatics, Cancer Prevention and Outreach programmes, and the Ayushmati women's cancer screening initiative. NCI also operates a city-centre Surgical Oncology facility, a dedicated Paediatric Oncology ward, and Radiotheranostics. Quality is reinforced through NABH Full Accreditation (6th Edition), NABL accreditation (ISO 15189:2022), and Kayakalp certification. The institute has no public API or developer programme.

Differentiator

Problem solved

Functional benefit

Brands

• Ayushmati: NCI's flagship programme for women's freedom from fear of cancer - a comprehensive initiative for breast cancer screening and women's health awareness
• Swasti Niwas
• Kark Yoddhas

Products and services

• Cancer Diagnostics Comprehensive cancer diagnostic services including CT Scan, MRI, PET Scan, Mammography, Ultrasound, X-Ray, ECG, 2D Echo, Color Doppler, Gamma Camera, and laboratory services (Clinical Biochemistry, Hematology, Microbiology, Histopathology, Cytopathology, Virology) for cancer diagnosis and staging. Targeted at patients requiring cancer evaluation.
• Cancer Therapeutics Full-spectrum cancer treatment including Medical Oncology, Surgical Oncology, Radiation Oncology, Hemato-Oncology, Nuclear Medicine, and Pain & Palliative Care delivered to cancer patients across solid tumours and blood cancers.
• Paediatric Oncology Dedicated paediatric oncology department with a 27-bed specialised ward including 3 Paediatric ICUs catering to children aged 0-14 years with cancer; free cancer treatment is provided to children under this service.
• Bone Marrow Transplant Haemato-oncology and Bone Marrow Transplant unit providing stem cell transplantation for blood cancers including leukemia, lymphoma, and multiple myeloma.
• Nuclear Medicine and Radiotheranostics Nuclear medicine department offering PET scan, functional imaging, therapeutic nuclear medicine, and the newly launched Radiotheranostics facility for treatment of thyroid, neuroendocrine, prostate, and other cancers by combining diagnosis and targeted therapy.
• Ayushmati Women's Cancer Screening Programme NCI's flagship programme offering free breast cancer screening for women above age 40 along with awareness initiatives targeting cancers prevalent among women, including cervical and oral cancer.
• Free Cervical Cancer Screening and HPV Vaccination Programme Free cervical cancer screening offering WHO-recommended HPV testing, follow-up care, and HPV vaccination; targets women aged 30-65 for screening and girls aged 9-14 for vaccination.
• Oncology Academic and Training Programmes Specialised oncology courses including Post Basic Diploma in Oncology Nursing (PBDON), Post Graduate Diploma in Oncology Care (PGDOC), and an MSc in Nuclear Medicine and Medical Physics, offered to medical professionals, nurses, and allied health workers.
• MSc Programme in Nuclear Medicine and Medical Physics Postgraduate MSc programme in Nuclear Medicine and Medical Physics aimed at building national capacity of skilled human resources for cancer diagnosis and treatment, offered through IIT Kharagpur's School of Medical Science and Technology.
• Cancer Research Basic, clinical, and epidemiological research programmes, early-phase clinical trials, and collaborative research with national and international institutions including IIT Bombay, AIIMS New Delhi, and other partners.
• In-Patient Services Hospital in-patient accommodation with 470 beds (scalable to 700), including a dedicated 27-bedded paediatric ward with 3 paediatric ICUs, private wards, and surgical ICU for admitted cancer patients.
• Out-Patient Services Out-patient consultations across all clinical departments, with online appointment booking available through the patient portal.
• Cancer Prevention and Outreach Community outreach programmes, health camps, school awareness activities, cancer screening drives, and tobacco control initiatives targeting prevention and early diagnosis of cancer across central India.
• City Centre Surgical Oncology Facility (Dharampeth) City-centre surgical oncology facility providing modular operation theatres, anaesthesia workstations, intra-operative frozen section, surgical ICU, and related surgical support services to patients requiring surgical oncology care in central Nagpur.

Quantifiable outcome

• NABH Full Accreditation - First hospital in Central India under 6th Edition
• +2 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature8 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Government of MaharashtracoreStrategic or Co-development Partner · 12 February 202612 MoUs signed with Tata Trusts to boost core areas in social sector including health. Partnerships aim to improve access to key services in underserved regions and enhance government efforts to reach the last mile in social service delivery.
• IIT KharagpurminorStrategic or Co-development Partner · 31 January 2026MoU with Variable Energy Cyclotron Centre (VECC) and Chittaranjan National Cancer Institute (CNCI) to jointly launch MSc programmes in nuclear medicine and medical physics. Programmes offered by School of Medical Science and Technology to strengthen cancer diagnosis, treatment, and advanced clinical research capabilities.
• AIIMS New DelhiminorStrategic or Co-development Partner · 1 January 2026Collaboration on cervical cancer screening program offering WHO-recommended HPV testing, follow-up care, and vaccination. Outreach and community screening drives conducted at NCI Jhajjar as part of Cervical Cancer Awareness Month.
• IIT BombaycoreTechnology or Integration · 24 September 2025Collaboration on CAR T-Cell therapy technology to treat cancer. IIT Bombay Professor Milind Atrey discussed establishing CAR T-Cell facility at NCI. Partnership for cyclotron and particle acceleration also planned, expected to revolutionize cancer treatment in Central India in 2-3 years.
• Government of GuyanacoreStrategic or Co-development Partner · 1 January 2025MoU signed for long-term partnership focused on research collaboration and delivering affordable cancer care. NCI to provide technical and institutional support to help Guyana develop comprehensive cancer care facility. Partnership aims to strengthen Guyana's national programme for sustainable and quality cancer care.
• Government of MauritiuscoreStrategic or Co-development Partner · 28 August 2024MoU signed for tertiary cancer treatment and training of doctors and nursing staff from Republic of Mauritius. People of Mauritius receive best cancer care at NCI Nagpur. Treatment is free for all citizens of Mauritius up to age 25. Doctors, nurses and medical staff from Mauritius receive training in oncology at NCI.
• NAAM FoundationminorGTM or Marketing Partner · 28 August 2024One MoU signed with NAAM Foundation alongside 12 MoUs with Tata Trusts to support social sectors including health, rural livelihoods, and nutrition.
• Maharashtra University of Health Sciences (MUHS), NashikminorStrategic or Co-development Partner · 7 August 2018Academic collaboration MoU signed for student exchange, faculty exchange, scholarships, conferences/workshops, research collaborations, and certificate, fellowship, diploma, degree, joint/dual degree programmes in health sciences.
• Tata TrustscoreStrategic or Co-development Partner · 14 July 2018Tata Trusts partnered with NCI to strengthen cancer care in Vidarbha region. Tata Trusts assist in upgradation of physical infrastructure and will help establish satellite cancer care facilities. Collaboration aims to provide comprehensive cancer care at affordable rates, reduce patient wait times, and improve clinical outcomes. Tata Trusts bring extensive experience in cancer care since 1942 with Tata Memorial Hospital and Tata Medical Center.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Tata Memorial Hospital: India's premier government-aided quaternary cancer center and the same Tata Trusts ecosystem that backs NCI. Directly comparable as a comprehensive oncology hospital offering diagnostics, surgery, radiation, and research — and is the benchmark NCI positions itself against.
• Tata Medical Center: Tata Trusts-built comprehensive cancer hospital in Kolkata. Comparable quaternary oncology care model with multi-specialty oncology services, research, and training, making it the closest operational peer within the Tata cancer-care portfolio.
• Chittaranjan National Cancer Institute (CNCI): Government of India regional cancer center with comprehensive oncology services. Direct peer as a multi-modality cancer hospital with research, diagnostics, and treatment — and a named collaborator with NCI via the IIT Kharagpur/VECC MSc program MoU.
• Cancer Institute (WIA), Adyar: Charitable, non-profit comprehensive cancer hospital in Chennai founded on a similar philanthropy-driven model. Direct peer in mission, structure, and service breadth (medical/surgical/radiation oncology, research, training).
• Rajiv Gandhi Cancer Institute and Research Centre: Non-profit comprehensive cancer hospital in Delhi offering multi-modality oncology, diagnostics, and research. Direct peer as another North/Central-India-relevant charitable cancer specialty hospital competing for similar patient segments.

Broad incumbents

• Healthcare Global Enterprises (HCG): India's largest dedicated oncology hospital chain with network presence across multiple cities. Broad incumbent in cancer care with overlapping services (medical/surgical/radiation oncology, diagnostics) but operates on a for-profit, multi-city model rather than a single-campus charity model.
• Apollo Cancer Centres: Cancer specialty arm of Apollo Hospitals, offering comprehensive oncology including advanced radiation and surgical oncology across metro India. Broad incumbent with deeper capital, larger catchment, and stronger medical-tourism brand.
• AIIMS New Delhi: India's flagship public tertiary/quaternary academic medical institution with a major oncology department and research programs. Broad incumbent overlapping on cancer care, training, and research — and an active NCI partner on cervical cancer screening.

Emerging players

• Cytecare Cancer Hospital: Bengaluru-based comprehensive cancer hospital offering organ-site-specific oncology care, molecular diagnostics, and research. Emerging player with overlapping capabilities (precision oncology, multi-modality treatment) but concentrated in a single metro.

Others

• Tata Institute of Fundamental Research (TIFR) - Cancer Research Programs: Adjacent research institution supporting cancer biology and translational research in India. Connected as part of the broader oncology research ecosystem but not a direct hospital competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/NCInagpur

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Cancer Institute